Journal
JOURNAL OF PHARMACOLOGICAL SCIENCES
Volume 140, Issue 2, Pages 201-204Publisher
JAPANESE PHARMACOLOGICAL SOC
DOI: 10.1016/j.jphs.2019.05.007
Keywords
Microautophagy; Chaperone-mediated autophagy; Rapamycin
Categories
Funding
- Japan Society for the Promotion of Science KAKENHI [16K08276]
- Grants-in-Aid for Scientific Research [16K08276] Funding Source: KAKEN
Ask authors/readers for more resources
Autophagy-lysosome proteolysis is classified into macroautophagy (MA), microautophagy (mA) and chaperone-mediated autophagy (CMA). In contrast to MA and CMA, mA have been mainly studied in yeast. In 2011, mammalian mA was identified as a pathway to deliver cytosolic proteins into multivesicular bodies. However, its molecular mechanism is quite different from yeast mA. Using a cell-based method to evaluate mA and CMA, we revealed that rapamycin, an activator of yeast mA, significantly activated mammalian mA. Although rapamycin activates MA, mA was also activated by rapamycin in MA-deficient cells. These findings suggest that rapamycin is a first-identified activator of mammalian mA. (C) 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available